한글목차

약물유전체학 시장 규모는 2023년 35억 달러에서 2028년에는 58억 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR은 10.6%에 달할 것으로 보이고 있습니다.

이 시장의 성장은 Drug Discovery와 약제 개발을 목적으로 한 연구개발 노력과 맞춤형 의료에 대한 주목의 증가에 기인하고 있습니다.

2022년, 세계의 약물유전체학 시장에서는 키트·시약 부문이 제품 유형별로 최대 점유율을 차지했습니다. 유전체학 연구를 위한 고품질 시약에 대한 수요의 증가, 맞춤형 의약품 시장 개발에 대한 주목의 증가, 유전체학 분야에서 연구 프로젝트의 증가 등의 요인이 이 시장의 성장을 촉진하고 있습니다.

아시아태평양은 예측 기간 중 가장 높은 성장률로 성장할 것으로 예측되고 있습니다. 첨단 시퀀스 기술의 채택 확대 및 헬스케어 분야의 호황 등 다양한 요인이 이 지역의 약물유전체학 시장의 성장을 지원하고 있습니다.

헬스케어 분야의 발전을 목적으로 한 제약회사 및 바이오테크놀러지 기업으로부터의 자금 제공 및 투자의 증가는 아시아태평양에서 약물유전체학 시장의 성장을 촉진할 것으로 기대되고 있습니다. 아시아는 연구개발(R&D) 투자에서 세계 최고의 지역이 되었으며, 세계 R&D 점유율의 44% 이상을 차지하고 있습니다. 이 지역은 매년 꾸준히 절반의 점유율을 추가하고 있으며, 이러한 추세가 지속될 경우 2030년까지 전체 R&D 투자의 절반 이상을 차지할 것으로 예상됩니다. 중국은 R&D 인프라와 인재 역량을 적극적으로 강화하고 있으며, 지출, 야망, 장기 계획에 대한 일관된 약속을 유지하고 있습니다. 이러한 요인들은 2023-2028년 이 지역에서 가장 높은 CAGR을 기록할 것으로 예상됩니다.

세계의 약물유전체학 시장에 대해 조사했으며, 제품·서비스별, 기술별, 용도별, 질환 영역별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 기술 분석
• 밸류체인 분석
• 공급망 분석
• 규제 상황
• 에코시스템 분석
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
• 2023-2024년의 주요 컨퍼런스와 이벤트
• Porter's Five Forces 분석
• 특허 분석
• 주요 이해관계자와 구입 기준

제6장 약물유전체학 시장, 제품·서비스별

• 서론
• 키트·시약
• 서비스

제7장 약물유전체학 시장, 기술별

• 서론
• 시퀀싱
• PCR
• 마이크로어레이
• 기타

제8장 약물유전체학 시장, 용도별

• 서론
• 맞춤형 의료
• 임상 연구
• Drug Discovery와 전임상 개발

제9장 약물유전체학 시장, 질환 영역별

• 서론
• 암
• 순환기 질환
• 신경학적 장애
• 기타

제10장 약물유전체학 시장, 최종사용자별

• 서론
• 학술연구기관
• 제약회사 및 바이오테크놀러지 기업
• CRO

제11장 약물유전체학 시장, 지역별

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제12장 경쟁 구도

• 개요
• 주요 참여 기업이 채택한 전략
• 매출 점유율 분석
• 시장 점유율 분석
• 기업 평가 매트릭스
• 스타트업/중소기업 평가 매트릭스
• 경쟁 벤치마킹
• 경쟁 시나리오

제13장 기업 개요

• 주요 참여 기업
  • ILLUMINA, INC.
  • THERMO FISHER SCIENTIFIC INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • QIAGEN
  • DANAHER CORPORATION
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • EUROFINS SCIENTIFIC
  • CHARLES RIVER LABORATORIES
  • BIO-RAD LABORATORIES, INC.
  • AGILENT TECHNOLOGIES, INC.
  • BECTON, DICKINSON AND COMPANY
  • REVVITY
  • IQVIA, INC.
  • MESA LABS, INC.
  • MEDPACE, INC.
  • MGI TECH CO., LTD.
• 기타 기업
  • PACBIO
  • TAKARA BIO INC.
  • NEW ENGLAND BIOLABS
  • BGI
  • NOVOGENE CO., LTD.
  • SOPHIA GENETICS
  • FIOS GENOMICS
  • PERSONALIS, INC.
  • NEOGENOMICS LABORATORIES
  • BIOAI HEALTH INC.
  • MACROGEN, INC.

제14장 부록

영문목차

The pharmacogenomics market is projected to reach USD 5.8 billion by 2028 from an estimated USD 3.5 billion in 2023, at a CAGR of 10.6% during the forecast period. The growth of this market can be attributed to the research and development efforts aimed at drug discovery and development, and growing focus on personalized medicines.

"The kits & reagents segment accounted for the largest share by product & service in 2022."

In 2022, the kits & reagents segment accounted for the largest share of product type in the global pharmacogenomics market. The factors such as growing demand for high quality reagents for genomics studies, increasing focus on development of personalized medicines, and growing number of research projects in the field of genomics are driving the growth of this market.

"The Asia Pacific region is growing in the pharmacogenomics market during the forecast period of 2023-2028."

The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including growing adoption of advanced sequencing technologies and booming healthcare sector are propelling the growth of pharmacogenomics market in the region.

Increased funding and investments from pharmaceutical and biotechnology companies aimed at advancing the healthcare sector are expected to propel the growth of the pharmacogenomics market in the Asia Pacific region. According to R&D Magazine, Asia has become the world's foremost region in research and development (R&D) investment, claiming over 44% of the global R&D share. The region is steadily gaining an additional half-percent share each year, and if this trend persists, it could represent more than half of all R&D investments by 2030. China is actively enhancing its R&D infrastructure and human resources capabilities, maintaining a consistent commitment to spending, ambition, and long-term planning. These factors are expected to contribute for the highest CAGR of the region between 2023 to 2028.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -30%, Europe -20%, Asia-Pacific -30%, Latin America -15% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• Eurofins Scientific (Luxembourg)
• Bio-Rad Laboratories, Inc. (US)
• Agilent Technologies, Inc. (US)
• BD (US)
• QIAGEN (Netherlands)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Revvity (US), IQVIA Inc. (US)
• Mesa Labs, Inc. (US)
• Medpace (US)
• MGI Tech Co., Ltd. (China)
• Takara Bio Inc. (Japan)
• PacBio (US)
• New England Biolabs (US)
• BGI (China), Novogene Co., Ltd. (China)
• SOPHiA GENETICS (Switzerland), Fios Genomics (UK)
• Personalis, Inc. (US)
• BioAI Health Inc. (US)
• NeoGenomics Laboratories (US)
• Macrogen, Inc. (South Korea).)

Research Coverage:

This research report categorizes the pharmacogenomics market by product & service (kits & reagents ( sequencing kits and reagents, PCR kits and reagents, microarray kits and reagents, and other kits & reagents) and service), technology (sequencing, PCR, microarray, and other technologies), disease area (cancer, cardiovascular, neurological diseases, and other disease areas), application (personalized medicine, clinical research, and drug discovery & preclinical development), and end user (academic & research institutes, pharmaeutical & biotechechnology companies, and contract research organization)

The report provides in-depth information on significant factors influencing the growth of the pharmacogenomics market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, mergers, and acquisitions within the pharmacogenomics market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmacogenomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (growing incidence and prevalence of chronic and genetic diseases and rising investments and funding to support genomic projects), restraints (challenges in data integration and interpretation, and issues related to drug response variability), opportunities (growing usage of genomics in specialized/personalized medicine), and challenges (ethical & regulatory issues, concern related to patient privacy & data accessibility) influencing the growth of the market.
• Product & Service Development/Innovation: Detailed insights on newly launched products/services of the pharmacogenomics market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the pharmacogenomics market
• Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
  • 1.2.2 MARKET SEGMENTATION
  • FIGURE 1 PHARMACOGENOMICS MARKET SCOPE
  • 1.2.3 YEARS CONSIDERED
• 1.3 CURRENCY
• 1.4 STAKEHOLDERS
• 1.5 LIMITATIONS
• 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 2 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • FIGURE 3 PHARMACOGENOMICS MARKET: BREAKDOWN OF PRIMARIES
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
  • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
    • 2.2.1.1 Insights from primaries
  • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.2.2 TOP-DOWN APPROACH
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• 2.3 GROWTH FORECAST
  • FIGURE 9 PHARMACOGENOMICS MARKET: CAGR PROJECTIONS
  • FIGURE 10 PHARMACOGENOMICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RECESSION IMPACT ANALYSIS
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
  • TABLE 2 US: HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
  • TABLE 3 US: HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

• FIGURE 12 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
• FIGURE 13 PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
• FIGURE 14 PHARMACOGENOMICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 15 PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD MILLION)
• FIGURE 16 PHARMACOGENOMICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 17 GEOGRAPHICAL SNAPSHOT OF PHARMACOGENOMICS MARKET

4 PREMIUM INSIGHTS

• 4.1 PHARMACOGENOMICS MARKET OVERVIEW
  • FIGURE 18 RISING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH
• 4.2 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022)
  • FIGURE 19 KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN PHARMACOGENOMICS MARKET IN 2022
• 4.3 PHARMACOGENOMICS MARKET SHARE, BY TECHNOLOGY, 2022
  • FIGURE 20 SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
• 4.4 PHARMACOGENOMICS MARKET SHARE, BY APPLICATION, 2022
  • FIGURE 21 PERSONALIZED MEDICINE SEGMENT DOMINATED MARKET IN 2022
• 4.5 PHARMACOGENOMICS MARKET SHARE, BY DISEASE AREA, 2022
  • FIGURE 22 CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF PHARMACOGENOMICS MARKET IN 2022
• 4.6 PHARMACOGENOMICS MARKET SHARE, BY END USER, 2022
  • FIGURE 23 ACADEMIC & RESEARCH INSTITUTES SEGMENT DOMINATED MARKET IN 2022
• 4.7 PHARMACOGENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 24 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 25 PHARMACOGENOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 4 PHARMACOGENOMICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing incidence and prevalence of chronic and genetic diseases
  • FIGURE 26 NUMBER OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA, 2023
    • 5.2.1.2 Rising investments and funding to support genomics projects
    • 5.2.1.3 Rising incidence of cancer
  • TABLE 5 CANCER INCIDENCE, 2020 VS. 2040
  • TABLE 6 CANCER PGX-RELATED PHARMACOGENES, DRUG PATHWAYS, AND CANCER DRUGS WITH SIDE EFFECTS
    • 5.2.1.4 Increasing collaborations and partnerships between key players and research institutes
  • TABLE 7 COLLABORATIONS AND PARTNERSHIPS BETWEEN KEY PLAYERS AND RESEARCH INSTITUTES
    • 5.2.1.5 Increasing focus on translational approach to optimize drug development processes
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Challenges in data integration and interpretation
    • 5.2.2.2 Issues related to drug response variabilities
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Use of genomics in specialized/personalized medicine
    • 5.2.3.2 AI in pharmacogenomics
    • 5.2.3.3 Increasing cost-effectiveness of pharmacogenomics testing
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Ethical and regulatory hurdles
    • 5.2.4.2 Growing concerns related to patient privacy and data access
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 SEQUENCING
  • TABLE 8 COMPARISON OF SANGER SEQUENCING AND NGS
  • 5.3.2 PCR
  • TABLE 9 COMPARISON OF PCR TECHNOLOGIES
  • 5.3.3 MICROARRAY
• 5.4 VALUE CHAIN ANALYSIS
  • FIGURE 27 PHARMACOGENOMICS MARKET: VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
  • FIGURE 28 PHARMACOGENOMICS MARKET: SUPPLY CHAIN ANALYSIS
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.6.2 REGULATORY SCENARIO
  • TABLE 14 PHARMACOGENOMICS MARKET: REGULATORY SCENARIO
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 PHARMACOGENOMICS PRODUCT VENDORS
  • TABLE 15 PHARMACOGENOMICS PRODUCT VENDORS: ROLE IN ECOSYSTEM
  • 5.7.2 PHARMACOGENOMICS SERVICE VENDORS
  • TABLE 16 PHARMACOGENOMICS SERVICE VENDORS: ROLE IN ECOSYSTEM
  • 5.7.3 PHARMACOGENOMICS END USERS
  • TABLE 17 PHARMACOGENOMICS END USERS: ROLE IN ECOSYSTEM
  • 5.7.4 PHARMACOGENOMICS REGULATORY BODIES
  • TABLE 18 PHARMACOGENOMICS REGULATORY BODIES: ROLE IN ECOSYSTEM
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 29 REVENUE SHIFT AND NEW REVENUE POCKETS
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER
  • TABLE 19 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER (2022)
  • 5.9.2 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION
  • TABLE 20 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION (2022)
  • 5.9.3 AVERAGE SELLING PRICE TREND ANALYSIS
  • FIGURE 30 GENOME SEQUENCING PRICING TREND
• 5.10 KEY CONFERENCES AND EVENTS IN 2023-2024
  • TABLE 21 PHARMACOGENOMICS MARKET: LIST OF CONFERENCES AND EVENTS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 22 PHARMACOGENOMICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 PATENT ANALYSIS
  • FIGURE 31 PATENT APPLICATIONS FOR PHARMACOGENOMICS MARKET, JANUARY 2013-DECEMBER 2023
  • TABLE 23 INDICATIVE LIST OF PATENTS IN PHARMACOGENOMICS MARKET
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES
  • TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES
  • 5.13.2 BUYING CRITERIA FOR PHARMACOGENOMICS MARKET
  • FIGURE 33 BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS
  • TABLE 25 BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS AND SERVICES, BY END USER

6 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 26 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
• 6.2 KITS & REAGENTS
  • TABLE 27 PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 28 PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 29 NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 30 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 32 LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 33 MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 34 MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.1 SEQUENCING KITS & REAGENTS
    • 6.2.1.1 Development of new sequencing technologies to drive market
  • TABLE 35 SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 36 NORTH AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 37 EUROPE: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 39 LATIN AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 40 MIDDLE EAST & AFRICA: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 41 MIDDLE EAST: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.2 PCR KITS & REAGENTS
    • 6.2.2.1 Ensures standardized and reliable identification of genetic variants related to drug metabolism
  • TABLE 42 PCR KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 44 EUROPE: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 46 LATIN AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 47 MIDDLE EAST & AFRICA: PCR KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 48 MIDDLE EAST: PCR KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.3 MICROARRAY KITS & REAGENTS
    • 6.2.3.1 Cost-effectiveness and high-throughput capabilities to support adoption
  • TABLE 49 MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 51 EUROPE: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 53 LATIN AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 54 MIDDLE EAST & AFRICA: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 55 MIDDLE EAST: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.2.4 OTHER KITS & REAGENTS
  • TABLE 56 OTHER KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 57 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 58 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 60 LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 61 MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 62 MIDDLE EAST: OTHER KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 6.3 SERVICES
  • 6.3.1 SCALABILITY OF CRO SERVICES ALLOWS TAILORED SOLUTIONS
  • TABLE 63 PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 64 NORTH AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 65 EUROPE: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 67 LATIN AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 68 MIDDLE EAST & AFRICA: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 69 MIDDLE EAST: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)

7 PHARMACOGENOMICS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
  • TABLE 70 PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
• 7.2 SEQUENCING
  • 7.2.1 GROWING ADOPTION OF GENETIC TESTING FOR DIAGNOSIS AND TREATMENT TO DRIVE MARKET
  • TABLE 71 SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 72 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 73 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 75 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 76 MIDDLE EAST & AFRICA: SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 77 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION)
• 7.3 PCR
  • 7.3.1 INCREASED USE OF PCR FOR DRUG AND BIOMARKER DISCOVERY TO PROPEL MARKET
  • TABLE 78 PCR MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 79 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 80 EUROPE: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 82 LATIN AMERICA: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 83 MIDDLE EAST & AFRICA: PCR MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 84 MIDDLE EAST: PCR MARKET, BY REGION, 2021-2028 (USD MILLION)
• 7.4 MICROARRAY
  • 7.4.1 MICROARRAY HELPS UNDERSTAND GENETIC BASIS OF DRUG METABOLISM
  • TABLE 85 MICROARRAY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 86 NORTH AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 87 EUROPE: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 89 LATIN AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 90 MIDDLE EAST & AFRICA: MICROARRAY MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 91 MIDDLE EAST: MICROARRAY MARKET, BY REGION, 2021-2028 (USD MILLION)
• 7.5 OTHER TECHNOLOGIES
  • TABLE 92 OTHER TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 93 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 94 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 96 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 97 MIDDLE EAST & AFRICA: OTHER TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 98 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)

8 PHARMACOGENOMICS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
  • TABLE 99 PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 8.2 PERSONALIZED MEDICINE
  • 8.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • TABLE 100 PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 101 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 102 EUROPE: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 104 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 105 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 106 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
• 8.3 CLINICAL RESEARCH
  • 8.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR PHARMACOGENOMICS TO DRIVE MARKET
  • TABLE 107 PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 108 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 109 EUROPE: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 111 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 112 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 113 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021-2028 (USD MILLION)
• 8.4 DRUG DISCOVERY & PRECLINICAL DEVELOPMENT
  • 8.4.1 INCREASING APPLICATIONS OF PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH
  • TABLE 114 PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 115 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 116 EUROPE: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 118 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 119 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 120 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)

9 PHARMACOGENOMICS MARKET, BY DISEASE AREA

• 9.1 INTRODUCTION
  • TABLE 121 PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
• 9.2 CANCER
  • 9.2.1 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET
  • TABLE 122 PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 123 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 124 EUROPE: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 126 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 127 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 128 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
• 9.3 CARDIOVASCULAR DISEASE
  • 9.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH
  • TABLE 129 PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 130 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 131 EUROPE: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 133 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 134 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 135 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2028 (USD MILLION)
• 9.4 NEUROLOGICAL DISORDERS
  • 9.4.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
  • TABLE 136 PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 137 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 138 EUROPE: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 140 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 141 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 142 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION)
• 9.5 OTHER DISEASE AREAS
  • TABLE 143 PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 144 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 145 EUROPE: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 147 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 148 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 149 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION)

10 PHARMACOGENOMICS MARKET, BY END USER

• 10.1 INTRODUCTION
  • TABLE 150 PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.2 ACADEMIC & RESEARCH INSTITUTES
  • 10.2.1 INCREASING RESEARCH ACTIVITIES AND FUNDING TO DRIVE GROWTH
  • TABLE 151 PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 152 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 153 EUROPE: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 155 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 156 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 157 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
• 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.3.1 GROWING STRATEGIC ALLIANCES FOR DRUG DEVELOPMENT AND PERSONALIZED MEDICINE TO PROPEL MARKET
  • TABLE 158 PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 159 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 160 EUROPE: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 162 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 164 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
• 10.4 CONTRACT RESEARCH ORGANIZATIONS
  • 10.4.1 INCREASING OUTSOURCING TREND IN GENOMICS FIELD TO PROPEL MARKET
  • TABLE 165 PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 166 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 167 EUROPE: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 169 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 171 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)

11 PHARMACOGENOMICS MARKET, BY REGION

• 11.1 INTRODUCTION
  • TABLE 172 PHARMACOGENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 11.2 NORTH AMERICA
  • FIGURE 34 NORTH AMERICA: PHARMACOGENOMICS MARKET SNAPSHOT
  • TABLE 173 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 174 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 175 NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 176 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 177 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 178 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 179 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.1 US
    • 11.2.1.1 US dominates North American pharmacogenomics market
  • TABLE 180 US: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 181 US: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 182 US: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 183 US: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 184 US: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 185 US: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.2 CANADA
    • 11.2.2.1 Growing research activities in genomics field to drive market
  • TABLE 186 CANADA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 187 CANADA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 188 CANADA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 189 CANADA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 190 CANADA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 191 CANADA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.3 RECESSION IMPACT ON NORTH AMERICAN PHARMACOGENOMICS MARKET
• 11.3 EUROPE
  • TABLE 192 EUROPE: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 193 EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 194 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 195 EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 196 EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 197 EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 198 EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.1 GERMANY
    • 11.3.1.1 Growing strategic alliances among industry players and research institutes to support market growth
  • TABLE 199 GERMANY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 200 GERMANY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 201 GERMANY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 202 GERMANY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 203 GERMANY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 204 GERMANY: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.2 UK
    • 11.3.2.1 Increasing government funding for genomics projects to propel market
  • TABLE 205 UK: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 206 UK: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 207 UK: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 208 UK: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 209 UK: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 210 UK: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.3 FRANCE
    • 11.3.3.1 Increasing government initiatives to boost market growth
  • TABLE 211 FRANCE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 212 FRANCE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 213 FRANCE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 214 FRANCE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 215 FRANCE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 216 FRANCE: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.4 ITALY
    • 11.3.4.1 Favorable funding programs to support market growth
  • TABLE 217 ITALY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 218 ITALY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 219 ITALY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 220 ITALY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 221 ITALY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 222 ITALY: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.5 SPAIN
    • 11.3.5.1 Government funding for research in pharmacogenomics and precision medicine to drive market
  • TABLE 223 SPAIN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 224 SPAIN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 225 SPAIN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 226 SPAIN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 227 SPAIN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 228 SPAIN: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.6 REST OF EUROPE
  • TABLE 229 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 230 REST OF EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 231 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 232 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 233 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 234 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.7 RECESSION IMPACT ON EUROPEAN PHARMACOGENOMICS MARKET

• 11.4 ASIA PACIFIC
  • FIGURE 35 ASIA PACIFIC: PHARMACOGENOMICS MARKET SNAPSHOT
  • TABLE 235 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 237 ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.1 CHINA
    • 11.4.1.1 Increasing research and development spending to support market growth
  • TABLE 242 CHINA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 243 CHINA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 244 CHINA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 245 CHINA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 246 CHINA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 247 CHINA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.2 JAPAN
    • 11.4.2.1 Growing focus on development of new pharmacogenomic services to drive market
  • TABLE 248 JAPAN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 249 JAPAN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 250 JAPAN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 251 JAPAN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 252 JAPAN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 253 JAPAN: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.3 INDIA
    • 11.4.3.1 Growing prevalence of chronic diseases to drive market
  • TABLE 254 INDIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 255 INDIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 256 INDIA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 257 INDIA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 258 INDIA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 259 INDIA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.4 AUSTRALIA
    • 11.4.4.1 Increase in research activities to propel market
  • TABLE 260 AUSTRALIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 261 AUSTRALIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 262 AUSTRALIA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 263 AUSTRALIA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 264 AUSTRALIA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 265 AUSTRALIA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Increasing investments in genomics research to drive market
  • TABLE 266 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 267 SOUTH KOREA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 268 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 269 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 270 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 271 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.6 REST OF ASIA PACIFIC
  • TABLE 272 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.7 RECESSION IMPACT ON ASIA PACIFIC PHARMACOGENOMICS MARKET
• 11.5 LATIN AMERICA
  • TABLE 278 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 279 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 280 LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 281 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 282 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 283 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 284 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.1 BRAZIL
    • 11.5.1.1 Increasing investments in biopharmaceutical research to propel market
  • TABLE 285 BRAZIL: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 286 BRAZIL: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 287 BRAZIL: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 288 BRAZIL: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 289 BRAZIL: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 290 BRAZIL: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.2 MEXICO
    • 11.5.2.1 Increasing genomics research activities to drive market
  • TABLE 291 MEXICO: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 292 MEXICO: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 293 MEXICO: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 294 MEXICO: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 295 MEXICO: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 296 MEXICO: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.3 REST OF LATIN AMERICA
  • TABLE 297 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 298 REST OF LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 299 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 300 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 301 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 302 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.4 RECESSION IMPACT ON LATIN AMERICAN PHARMACOGENOMICS MARKET
• 11.6 MIDDLE EAST & AFRICA
  • TABLE 303 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 304 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 305 MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 306 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 307 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 309 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.6.1 MIDDLE EAST
  • TABLE 310 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 311 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 312 MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 313 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 314 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 315 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 316 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.1.1 GCC countries
      • 11.6.1.1.1 Increasing government initiatives for pharmacogenomics to propel market
  • TABLE 317 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 318 GCC COUNTRIES: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 319 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 320 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 321 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 322 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.1.2 Rest of Middle East
  • TABLE 323 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 324 REST OF MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 325 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 326 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 327 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 328 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.6.2 AFRICA
    • 11.6.2.1 Growing prevalence of HIV & cancer to drive market
  • TABLE 329 AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 330 AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 331 AFRICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 332 AFRICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 333 AFRICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION)
  • TABLE 334 AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.6.3 RECESSION IMPACT ON MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • FIGURE 36 PHARMACOGENOMICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
• 12.3 REVENUE SHARE ANALYSIS
  • FIGURE 37 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PHARMACOGENOMICS MARKET, 2018-2022 (USD MILLION)
• 12.4 MARKET SHARE ANALYSIS
  • FIGURE 38 PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER (2022)
  • TABLE 335 PHARMACOGENOMICS MARKET: INTENSITY OF COMPETITIVE RIVALRY
• 12.5 COMPANY EVALUATION MATRIX
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • FIGURE 39 PHARMACOGENOMICS MARKET: COMPANY EVALUATION MATRIX (2022)
  • 12.5.5 COMPANY FOOTPRINT
  • TABLE 336 PRODUCT & SERVICE FOOTPRINT
  • TABLE 337 REGIONAL FOOTPRINT
• 12.6 STARTUP/SME EVALUATION MATRIX
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • FIGURE 40 PHARMACOGENOMICS MARKET: STARTUP/SME EVALUATION MATRIX (2022)
• 12.7 COMPETITIVE BENCHMARKING
  • TABLE 338 PHARMACOGENOMICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 339 PHARMACOGENOMICS MARKET: PRODUCT & SERVICE AND REGIONAL FOOTPRINT OF KEY STARTUPS/SMES
• 12.8 COMPETITIVE SCENARIO
  • TABLE 340 PHARMACOGENOMICS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020-DECEMBER 2023
  • TABLE 341 PHARMACOGENOMICS MARKET: DEALS, JANUARY 2020-DECEMBER 2023
  • TABLE 342 PHARMACOGENOMICS MARKET: OTHER DEVELOPMENTS, JANUARY 2020- DECEMBER 2023

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
• (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
• 13.1.1 ILLUMINA, INC.
• TABLE 343 ILLUMINA, INC.: BUSINESS OVERVIEW
• FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
• 13.1.2 THERMO FISHER SCIENTIFIC INC.
• TABLE 344 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
• FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
• 13.1.3 F. HOFFMANN-LA ROCHE LTD.
• TABLE 345 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
• FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
• 13.1.4 QIAGEN
• TABLE 346 QIAGEN: BUSINESS OVERVIEW
• FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2022)
• 13.1.5 DANAHER CORPORATION
• TABLE 347 DANAHER CORPORATION: BUSINESS OVERVIEW
• FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
• 13.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
• TABLE 348 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
• FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
• 13.1.7 EUROFINS SCIENTIFIC
• TABLE 349 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
• FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
• 13.1.8 CHARLES RIVER LABORATORIES
• TABLE 350 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
• FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
• 13.1.9 BIO-RAD LABORATORIES, INC.
• TABLE 351 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
• FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
• 13.1.10 AGILENT TECHNOLOGIES, INC.
• TABLE 352 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
• FIGURE 50 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
• 13.1.11 BECTON, DICKINSON AND COMPANY
• TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
• FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
• 13.1.12 REVVITY
• TABLE 354 REVVITY: BUSINESS OVERVIEW
• FIGURE 52 REVVITY: COMPANY SNAPSHOT (2022)
• 13.1.13 IQVIA, INC.
• TABLE 355 IQVIA, INC.: BUSINESS OVERVIEW
• FIGURE 53 IQVIA, INC.: COMPANY SNAPSHOT (2022)
• 13.1.14 MESA LABS, INC.
• TABLE 356 MESA LABORATORIES, INC.: BUSINESS OVERVIEW
• FIGURE 54 MESA LABS, INC.: COMPANY SNAPSHOT (2022)
• 13.1.15 MEDPACE, INC.
• TABLE 357 MEDPACE, INC.: BUSINESS OVERVIEW
• FIGURE 55 MEDPACE, INC.: COMPANY SNAPSHOT (2022)
• 13.1.16 MGI TECH CO., LTD.
• TABLE 358 MGI TECH CO., LTD.: BUSINESS OVERVIEW
• FIGURE 56 MGI TECH CO., LTD.: COMPANY SNAPSHOT (2022)
• 13.2 OTHER PLAYERS
  • 13.2.1 PACBIO
  • TABLE 359 PACBIO: COMPANY OVERVIEW
  • 13.2.2 TAKARA BIO INC.
  • TABLE 360 TAKARA BIO INC.: COMPANY OVERVIEW
  • 13.2.3 NEW ENGLAND BIOLABS
  • TABLE 361 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • 13.2.4 BGI
  • TABLE 362 BGI: COMPANY OVERVIEW
  • 13.2.5 NOVOGENE CO., LTD.
  • TABLE 363 NOVOGENE CO., LTD.: COMPANY OVERVIEW
  • 13.2.6 SOPHIA GENETICS
  • TABLE 364 SOPHIA GENETICS: COMPANY OVERVIEW
  • 13.2.7 FIOS GENOMICS
  • TABLE 365 FIOS GENOMICS: COMPANY OVERVIEW
  • 13.2.8 PERSONALIS, INC.
  • TABLE 366 PERSONALIS, INC.: COMPANY OVERVIEW
  • 13.2.9 NEOGENOMICS LABORATORIES
  • TABLE 367 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
  • 13.2.10 BIOAI HEALTH INC.
  • TABLE 368 BIOAI HEALTH INC.: COMPANY OVERVIEW
  • 13.2.11 MACROGEN, INC.
  • TABLE 369 MACROGEN, INC.: COMPANY OVERVIEW
• *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS